Lyell Wealth Management LP Sells 7,750 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Lyell Wealth Management LP reduced its position in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT) by 15.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 41,930 shares of the company’s stock after selling 7,750 shares during the period. Lyell Wealth Management LP owned about 0.08% of PROCEPT BioRobotics worth $3,376,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the company. KRS Capital Management LLC boosted its position in PROCEPT BioRobotics by 0.5% during the fourth quarter. KRS Capital Management LLC now owns 46,455 shares of the company’s stock valued at $3,741,000 after purchasing an additional 225 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of PROCEPT BioRobotics during the third quarter worth approximately $27,000. KBC Group NV increased its stake in shares of PROCEPT BioRobotics by 32.6% during the third quarter. KBC Group NV now owns 1,531 shares of the company’s stock worth $123,000 after purchasing an additional 376 shares during the period. Raleigh Capital Management Inc. bought a new position in shares of PROCEPT BioRobotics during the fourth quarter worth approximately $32,000. Finally, Blue Trust Inc. increased its stake in shares of PROCEPT BioRobotics by 11.7% during the third quarter. Blue Trust Inc. now owns 4,441 shares of the company’s stock worth $356,000 after purchasing an additional 466 shares during the period. 89.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at PROCEPT BioRobotics

In other news, CEO Reza Zadno sold 26,420 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $97.83, for a total value of $2,584,668.60. Following the transaction, the chief executive officer now owns 179,185 shares in the company, valued at $17,529,668.55. The trade was a 12.85 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alaleh Nouri sold 28,092 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $97.13, for a total value of $2,728,575.96. Following the completion of the transaction, the executive vice president now owns 52,472 shares in the company, valued at $5,096,605.36. The trade was a 34.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 80,935 shares of company stock valued at $7,882,089 in the last three months. Corporate insiders own 17.40% of the company’s stock.

PROCEPT BioRobotics Price Performance

Shares of PROCEPT BioRobotics stock opened at $66.92 on Wednesday. PROCEPT BioRobotics Co. has a one year low of $45.20 and a one year high of $103.81. The business has a 50-day simple moving average of $78.51 and a 200 day simple moving average of $79.80. The company has a quick ratio of 5.07, a current ratio of 6.02 and a debt-to-equity ratio of 0.21.

Analyst Upgrades and Downgrades

PRCT has been the topic of a number of recent research reports. Jefferies Financial Group initiated coverage on PROCEPT BioRobotics in a research note on Thursday, November 14th. They set a “hold” rating and a $95.00 price objective on the stock. Wells Fargo & Company reissued an “overweight” rating and set a $112.00 price objective on shares of PROCEPT BioRobotics in a report on Tuesday, December 3rd. Morgan Stanley initiated coverage on PROCEPT BioRobotics in a research report on Monday, December 2nd. They set an “overweight” rating and a $105.00 target price for the company. Finally, Truist Financial reissued a “buy” rating and issued a $105.00 price objective (up from $95.00) on shares of PROCEPT BioRobotics in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, PROCEPT BioRobotics presently has an average rating of “Moderate Buy” and a consensus price target of $97.86.

About PROCEPT BioRobotics

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).